For personal use only

2021 Q3 Results Investor Briefing

Sydney, Australia, Tuesday, 19 October 2021: Next Science Limited (ASX:NXS) advises that it intends to release its results for the quarter ending 30 September 2021 on Thursday, 28 October 2021.

Next Science's Managing Director, Judith Mitchell, will host an investor conference call at **9.30am** (Sydney time) on **Monday, 1 November 2021** to discuss the results. The briefing is expected to last approximately 45 minutes inclusive of question time.

To pre-register for the call, please use the following link:

https://teams.microsoft.com/registration/WNk1SjeGuEa6hOStBhDN0A,ipmPmq0W_USVmiygX91aIA,zQqYBYy1Okyp9-pN5EK2dQ,Yd3zqvZfi0Syc9WgLQOmXg,6UajldBEnUW-qvdG_J__pg,qA_jvPec_0SobJ-6N4-IeQ?mode=read&tenantId=4a35d958-8637-46b8-ba84-e4ad0610cdd0

Approved and authorised by Judith Mitchell, Managing Director, Next Science Limited.

Further information:

Judith Mitchell
Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown
Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: www.nextscience.com**.**